May 2011

Substantial outreach efforts are needed in addition to offering subsidies or incentives in engaging primary care providers to adopt electronic health records.

Three approaches to prospective patient identification for care management programs were compared: predictive modeling, selection by primary care physician, and a combination of both.

The upward trend in total and outpatient healthcare expenditures in the United States appears to be unrelated to psychological distress.

Adherence to colon cancer post-treatment surveillance was low, although proportions of patients complying with office visits and colonoscopy were reasonably high.

Providers expect that patients with chronic conditions will complete necessary laboratory tests; 1 in 7 patients with diabetes did not do so within 6 months.

The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.

We measured the financial consequences of new CRC treatment regimens. New regimens have increased cost directly through price and indirectly through nonstandard and second-line regimen use.

An oral chemotherapy cycle management program offers clinical support, reduces medication wastage, and provides management of adverse effects to realize cost savings for payers and patients.

Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.

Evaluating current models and diagnosing successful strategies for payers and physicians.

WellPoint, UCLA's Jonsson Comprehensive Cancer Center, the National Coalition for Cancer Survivorship (NCCS) and Genentech collaborated to develop Journey Forward, a first-of-its-kind program for coordinating post-treatment care.

This study presents Humana's experience with a multigene breast cancer assay and provides an analysis of the clinical utility and economics of this technology.

The pay-for-performance program for breast cancer care had a positive impact on breast cancer outcome in Taiwan. Enrollees received better quality care and had better outcome.